Abstract: Biodegradable personal care compositions comprising 1,3-propanediol are provided, and the 1,3-propanediol in the composition is biologically derived. The compositions exhibit a lower anthropogenic CO2 emission profile. Also provided are biodegradable personal care compositions comprising an ester of 1,3-propanediol. In these compositions, the ester can have at least 3% biobased carbon.
Type:
Grant
Filed:
May 25, 2010
Date of Patent:
November 1, 2011
Assignee:
DuPont Tate & Lyle Bio Products Company, LLC
Inventors:
Melissa Joerger, Gyorgyi Fenyvesi, Raja Hari Poladi, Ann Wehner, Irwin A. Palefsky
Abstract: The present invention employs the natural hydrophilic properties of a macromolecular film such as a hydrogel and in combination with localized photo-ablation of monolayers created with the hydrogel using multi-photon laser excitation, provides a stampless, versatile method of micropattern fabrication.
Type:
Grant
Filed:
October 10, 2008
Date of Patent:
November 1, 2011
Assignee:
The United States of America as represented by the Secretary, Department of Health and Human Services
Inventors:
Andrew D. Doyle, Kenneth M. Yamada, Francis W. Wang
Abstract: Provided herein are methods of preventing, lessening or treating pulmonary fibrosis in a subject. The methods comprise delivering an amount of a powdered extracellular matrix (ECM)-derived material to the respiratory system of the subject effective to prevent, lessen or treat pulmonary fibrosis in a subject. Also provided is an apparatus for delivering the powdered ECM-derived material to a subject.
Type:
Application
Filed:
December 4, 2009
Publication date:
October 27, 2011
Applicant:
University of Pittsburgh-Of the Commonwealth System of Higher Education
Inventors:
Thomas Gilbert, Michelle Manni, Tim D. Oury
Abstract: A method for determining the redox status of a protein sample, the method comprising the steps of: a) contacting the sample with a first label adapted to bind to at least one reduced cysteine group therein; b) contacting the sample with a reducing agent to reduce at least one oxidized cysteine group therein; c) contacting the sample with a second label adapted to bind to any reduced cysteine groups produced in step (b); and d) determining the ratio of the signal from the first label to the signal from the second label wherein the ratio indicates the redox status.
Type:
Grant
Filed:
May 22, 2008
Date of Patent:
October 25, 2011
Assignee:
Proteomics International Pty Ltd.
Inventors:
Richard J. Lipscombe, Peter G. Arthur, James K. Lui
Abstract: The present invention relates to an antimicrobial composition, and to a process for the preparation of such a composition. The invention also relates to the use of such an antimicrobial composition. The present invention further relates to the use of the antimicrobial composition as a pharmaceutical.
Abstract: A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.
Abstract: Breast cancer is a common cancer in women. Early diagnosis and treatments are vital for better outcomes. This formula consists of a liquid anti-disease anti-cancer formula that can be delivered to the source where breast cancer begins. Method of treating breast disease, including cancer, with a formula and a means of delivery with a topical, intraductal, ductal, and/or intraductal infusion to prevent the formation of cancer or precursors to cancer or atypia or other form of abnormal breast tissue or to treat breast diseases of all kinds. May include homeopathic remedies to be used topically or inside the breast with a delivery method to those regions and may be processed with or without photonic programming or an ionic delivery system for greater effectiveness and use against degenerative diseases or cancerous or precancerous diseases, precursors of breast disease, inflammatory breast disease, or accumulation of toxins in the breast tissue.
Abstract: Methods for promoting angiogenesis comprising administering platelet-rich plasma to a site and stimulating the site with an electromagnetic field. Platelets include platelet-rich plasma and compositions can further include stem cells such as adipose stromal cells and cells derived from bone marrow aspirate. Methods also comprise isolating platelets from a patient's blood, forming a composition including the platelets, delivering the composition to a site in need of treatment, and electrically stimulating the site.
Type:
Grant
Filed:
March 6, 2007
Date of Patent:
October 11, 2011
Assignee:
Biomet Biologics, LLC
Inventors:
Joel C. Higgins, Bruce Simon, Jennifer E. Woodell-May
Abstract: A novel method of preparing a controlled release composition is disclosed. Specifically, the present invention relates to a method of preparing controlled release compositions of ascorbic acid phosphate and absorbable polymers. Also disclosed is a novel controlled release composition of ascorbic acid phosphate made by the method of the present invention.
Type:
Grant
Filed:
December 11, 2008
Date of Patent:
October 11, 2011
Assignee:
Advanced Technologies and Regenerative Medicine, LLC.
Abstract: A method for characterizing oxidative stress. The method includes dosing a ratio of HNE-to-DHN-protein in blood; comparing the ratio of HNE-to-DHN-protein in blood to a predetermined interval of ratio values associated with a predetermined level of oxidative stress; and classifying the oxidative stress as having reached the predetermined level if the ratio of HNE-to-DHN-protein in blood is within the predetermined interval of ratio values.
Type:
Grant
Filed:
October 13, 2006
Date of Patent:
October 4, 2011
Assignee:
Institut de Cardiologie de Montreal
Inventors:
Christine Des Rosiers, Caroline Asselin, Bertrand Bouchard, Jean-Claude Tardif, Blandine Comte
Abstract: Presented herein are novel blood plasma/serum biomarkers related to cardiovascular disease. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction (MI). A multiplexed, mass spectrometric immunoassay (MSIA) able to simultaneously assay for the new/novel biomarkers as well other MI markers is also presented. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the multiplexed MI assay in clinical, diagnostic and therapeutic uses is also included.
Type:
Grant
Filed:
October 18, 2010
Date of Patent:
October 4, 2011
Assignee:
Intrinsic Bioprobes, Inc.
Inventors:
Urban A. Kiernan, Dobrin Nedelkov, Randall W. Nelson
Abstract: A skincare composition comprising Gorgonian extract as an anti-inflammatory component thereof, said skincare composition being selected from among compositions (I) and (II): (I) an aqueous composition comprising from 35 to 65 wt.% water, from 25 to 45 wt.% surfactant, from 0.01 to 0.2 wt.% retinol and from 0.005 to 0.5 wt.% Gorgonian extract, wherein all weight percentages are based on total weight of the aqueous face wash composition, and all weight percentages of all ingredients in the aqueous face wash composition total to 100 wt. %; and (II) a gel composition comprising from 60 to 90 wt.% water, from 1 to 12 wt.% benzoyl peroxide, and from 0.05 to 1.25 wt.% Gorgonian extract, wherein all weight percentages are based on total weight of the gel composition, and all weight percentages of all ingredients in the gel composition total to 100 wt.%.
Abstract: Devices and methods for treating or repairing a tissue or organ defect or injury are provided. The devices can include tissue scaffolds produced from acellular tissue matrices and polymers, which have a stable three-dimensional shape and elicit a limited immunologic or inflammatory response.
Type:
Application
Filed:
March 24, 2011
Publication date:
September 29, 2011
Inventors:
Rick Owens, Wendell Sun, Mike Liu, Yong Mao
Abstract: Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphorylation reaction of the phosphorylated coenzyme coexist with the phosphorylated coenzyme.
Abstract: The present invention relates to a method of extracting mesenchymal stem cells from human or animal embryo, comprising: A. taking the sample based on human or animal embryo, centrifuging the sample; B. digesting the sample with enzyme digestion solution, and making single cell suspension, wherein said enzyme digestion solution comprises trysin-EDTA and collagenase IV; C. adding mesenchymal stem cell culture medium A to the isolated single cells, inoculating and culturing the cells; D. treating the cells with adherence purification, and obtaining mesenchymal stem cells by magnetic sorting. The present invention also relates to a method of extracting the secretion product from mesenchymal stem cells, the use of the secretion product in the aspects of cosmetic and healthcare, and an epidermal cell repairing lotion made using the secretion product.
Type:
Application
Filed:
September 18, 2009
Publication date:
September 8, 2011
Applicant:
TEAM YOUN BIOMEDICAL TECHNOLOGY CO., LTD.
Abstract: Methods of using microarrays to simplify analysis and characterization of genes and their function are provided. Such methods can be used to identify and characterize antibodies having binding affinity for a specific target antigen. A method of determining gene expression at the protein level by contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds also is provided. This method can be used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells. In addition, a method of determining gene expression at the protein level by contacting a microarray of nucleic acid samples derived from a variety of different sources with one or more nucleic acid probes then identifying the sample or samples to which the probe binds is provided.
Type:
Grant
Filed:
June 23, 2009
Date of Patent:
September 6, 2011
Assignee:
Life Technologies Corporation
Inventors:
James Hoeffler, Joseph Fernandez, Marc Nasoff
Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
Abstract: This invention is directed to coral scaffolds seeded with precursor cells in culture in the presence of a chelator and uses thereof in inducing or enhancing bone and/or cartilage formation in a subject, and kits related thereto. This invention is also directed to use of cadherin-upregulating coral for treating cancer or inhibiting cancer progression. This invention is also directed to use of aragonite or calcite-producing species for in vivo calcium release, and its application to the treatment of skin diseases, disorders or conditions.
Abstract: The present invention relates to a method of screening placental proteins responsible for pathophysiology of preeclampsia, and a marker for early diagnosis and prediction of preeclampsia. In accordance with one aspect of the present invention, there is provided a method of screening placental proteins responsible for pathophysiology of preeclampsia by 2D E-proteomics analysis, comprising: isolating placental proteins from a placental tissue; separating the isolated proteins two-dimensionally through 2D electrophoresis; and comparing and analyzing the separated proteins based on scanned gel images and differences in the images between normal placental proteins and preeclamptic placental proteins, wherein the comparison and analysis of the placental proteins based on the scanned gel images and differences in the images are accomplished by selecting proteins with differences of 140% or more between two placentas.
Type:
Grant
Filed:
July 16, 2008
Date of Patent:
August 16, 2011
Assignee:
Inje University Industry-Academic Cooperation Foundation
Abstract: A composition of matter comprising an agent beneficial to a non-skin keratinous substance and at least one stinging capsule and methods of use are disclosed.
Abstract: The invention relates to a coating composition for application to a veterinary pharmaceutical composition for oral administration, by a film coating method, comprising a powder appetising material a binder and a solvent. The invention further relates to a coating method by film coating of a solid veterinary pharmaceutical for oral administration and appetising medicaments for animals comprising a veterinary pharmaceutical composition and an appetising coating arranged around said composition, comprising an appetising material and a binder.
Abstract: A method and composition for treating dermatological conditions and improving skin condition and helping hair to grow or thicken involves putting mesenchymal stem cells or other cells with regenerative properties into culture medium to induce secretion of beneficial factors such as growth factor, regulatory factors, enzymes, hormones, peptides and lymphokines into the culture medium to create conditioned medium and then extracting either a supernatant or a cell free extract of the conditioned medium to use itself or components thereof alone or with other skin or hair care reagents as a topical ointment or formula to apply to the skin or hair topically for therapeutic and cosmetic purposes.
Abstract: This invention relates in one aspect to the treatment of a vascular vessel with a biomaterial. The biomaterial can be a remodelable material that strengthens and/or supports the vessel walls. Additionally the biomaterial can include a variety of naturally occurring or added bioactive agents and/or viable cellular populations.
Type:
Application
Filed:
March 15, 2011
Publication date:
July 14, 2011
Inventors:
Brian C. Case, Michael C. Hiles, Jacob A. Flagle, F. Joseph Obermiller, Umesh H. Patel
Abstract: Disclosed is: a visceral fat accumulation inhibitor or a food or drink for inhibiting the accumulation of a visceral fat, which composes a fat globule membrane component as an active ingredient; or a agent or food or drink for promoting the increase in the blood adiponection level and/or inhibiting the decrease in the blood adiponection level, which composes a fat globule membrane component as an active ingredient. A fat globule membrane component can inhibit the accumulation of a visceral fat, and/or can promote the increase in or inhibit the decrease in the blood adiponection level.
Abstract: The present invention relates to a composition containing an extracellular matrix for controlling aging and a method for controlling aging by using the same. The composition for controlling aging and the method for controlling aging have an effect for recovering the biological function of the aged aging cell, and the amount of the expression of the integrin alpha V that is a cell membrane protein and is reduced if aging is again increased in the aging cell recovered by the young extracellular matrix. However, when the amount of expression of the integrin alpha V is artificially decreased by using siRNA and antibody, the aging cell is not recovered by the extracellular matrix extracted from the young cell.
Type:
Application
Filed:
July 29, 2009
Publication date:
June 23, 2011
Inventors:
Sang Chul Park, Kyung A. Cho, Moon Kyung Ha, Hae Ri Choi
Abstract: The invention provides compositions and methods for modulating immune responses using mesenchymal stem cells. The invention further provides methods for inducing tolerance to self antigens using mesenchymal stem cells.
Type:
Application
Filed:
May 1, 2009
Publication date:
June 23, 2011
Applicants:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL, DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
Biju Parekkadan, Martin Leon Yarmush, Shannon J. Turley
Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.
Type:
Application
Filed:
February 11, 2011
Publication date:
June 16, 2011
Inventors:
Hendrik J. SCHUURMAN, Emanuele Luigi COZZI, Francoise RICHARD, Guy TACCARD, David James Graham WHITE, Peter John FRIEND, John WALLWORK, Paolo BRENNER
Abstract: There are disclosed skin treatment compositions containing cell signaling compounds, which induce and promote the biosynthesis and/or bioactivity of endogenous chemicals that mediate cell to cell communication in the skin between keratinocytes, fibroblasts and other cell types present in the skin. The cell signaling compound is selected from the group consisting of: andrographolide and its derivatives; adenosine cyclic phosphate and its derivatives; hydrolyzed milk proteins; sunflower seed extract; plankton extract; phytol and its derivatives; and mixtures thereof.
Type:
Grant
Filed:
January 21, 2005
Date of Patent:
June 14, 2011
Assignee:
Avon Products, Inc.
Inventors:
Glen T. Anderson, Dmitri S. Ptchelintsev, Gopinathan K. Menon, John A. Duffy
Abstract: The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure.
Type:
Application
Filed:
June 11, 2009
Publication date:
June 2, 2011
Inventors:
Maria Beatriz Herrera Sanchez, Valentina Fonsato, Tetta Ciro, Camussi Giovanni
Abstract: This invention describes method to facilitate intradermal delivery of a great variety of active substances, especially including high molecular weight cosmicuticals. Also disclosed is a method of applying the composition of matter resulting from the method topically to patients, especially using a cream or patch. The active substance is initially combined with a biopolymer, which combination is subsequently linked to a base formulation whereby the base formulation aids in the intra-dermal delivery of the active substance without the skin irritation limitations of other formulations and dermal transmitting methods. The method of using a combination of natural herbal, vegetable and animal products combined in this invention with biopolymers permits molecules of higher molecule weight to penetrate into the skin in a bioactive form by passive delivery means. The invention includes a method for the improvement of skin health and wrinkle reduction.
Abstract: A skin whitening cosmetic composition having excellent whitening effects without causing any side effects, which includes a carbonized pine cone, as well as a pack containing the same. The skin whitening cosmetic composition includes natural substances, unlike prior commercially available products, and has excellent whitening effects without causing any side effect since it is safe to the skin. When the whitening cosmetic composition is used as it is or as a pack together with a substrate, such as a nonwoven fabric, it will provide a functional pack that can impart whitening effects in addition to effects, such as skin moisturization and skin firming.
Abstract: The invention relates to a substance mixture on the basis of a mixture of essential oils, wherein the oil mixture contains juniper oil and turpentine oil, in particular turpentine oil of the duster pine type or substantially comprises them, and wherein the substance mixture preferably furthermore contains a liquid and/or dissolved active ingredient or a mixture of a plurality thereof and/or an active ingredient in powder form or a mixture of a plurality thereof.
Abstract: A composition comprising an extract from an aquatic organism is disclosed. The composition is capable of preventing adhesion of a cell to a surface and is devoid of cytotoxic or cytostatic activity. Medical devices comprising same and methods for preventing or treating a pathological infection using same are also disclosed.
Type:
Application
Filed:
September 21, 2008
Publication date:
May 19, 2011
Applicant:
TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND S
Inventors:
Amir Zlotkin, Eliahu Zlotkin, Amir Zlotkin
Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
Type:
Grant
Filed:
April 16, 2010
Date of Patent:
May 17, 2011
Assignee:
Board of Regents, the University of Texas System
Inventors:
Maher Albitar, Michael J. Keating, Taghi Manshouri
Abstract: The present disclosure relates to tailored glycoproteomic methods, and more particularly to methods for the sequencing, mapping and identification of cellular glycoproteins using saccharide-selective bioorthogonal probes. A method is disclosed for saccharide-selective glycoprotein identification (ID) and glycan mapping (GIDmap) that generates glycoproteins tailored with bioorthogonally tagged alkynyl saccharides that can be selectively isolated, allowing for glycoprotein ID and glycan mapping via mass spectromic proteomics, including liquid chromatography-tandmen mass spectroscopy (LC-MS2). LC-MS2 may be used to identify cellular glycans, and more specifically cancer-related glycoproteins.
Type:
Grant
Filed:
March 24, 2008
Date of Patent:
May 17, 2011
Assignee:
Academia Sinica
Inventors:
Chi-Huey Wong, Tsui-Ling Hsu, Sarah R Hanson
Abstract: A method and apparatus to estimate the concentration of a target substance (e.g. Cholesterol or CRP) in the plasma component of awhole blood sample without the need to separate the red blood cells from the plasma prior to testing, thereby simplfying the design and construction of the test device. The invention achieves this by measuring the analyte under investigation in a time dependent (bio-/immuno-) chemical reaction and measuring separately, a marker substance (e.g haemoglobin) for the estimation of red blood cell volume, using a non-time-dependent alteration in physical property of the reaction mixture (in this instance, transmission) attributed to inherent filter effects on sample addition. These non-time-dependent changes are not part of the reaction chemistry, and are resolved from the time dependent alteration in physical property caused by the assay chemistry by continuous measurement and mathematical modelling.
Type:
Grant
Filed:
March 20, 2008
Date of Patent:
May 17, 2011
Assignee:
Quotient Diagnostics Limited
Inventors:
John Phillip Vessey, Adrian Richard Gray, David Percival
Abstract: The present invention provides methods, systems, and code for accurately classifying or diagnosing a sample from an individual as an IBS sample. The methods and systems of the present invention are useful for ruling out one or more diseases or disorders that share a similar clinical presentation as IBS followed by identifying (i.e., ruling in) IBS using statistical algorithm(s) and/or empirical data. In particular, the methods and systems of the present invention use a first combination of learning statistical classifier systems to rule out IBD with an accuracy of greater than about 90% and a second combination of learning statistical classifier systems to rule in IBS in a non-IBD sample with an accuracy of greater than about 80%.
Abstract: The present invention relates to a pharmaceutical composition for preventing and treating cell proliferative diseases comprising a feather of birds and a scale of fish, a scale transformed from the dermis, a degenerated or cornified variant of a scale, or a scale or horny scale of reptiles as an active ingredient. More particularly, the present invention relates to a pharmaceutical composition for preventing and treating cell proliferative diseases comprising a mixture of 70-85 weight % of a feather of birds and 15-30 weight % of a scale of fish, a scale transformed from the dermis, a degenerated or cornified variant of a scale, or a scale or horny scale of reptiles as an active ingredient. The inventive composition has the effect of inhibiting and preventing growth of cancer cells. Accordingly, the inventive composition may be used for anticancer purposes to prevent, ameliorate or treat cancer.
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Type:
Application
Filed:
November 8, 2010
Publication date:
May 12, 2011
Inventors:
SCOTT WILLIAM BAGLEY, DAVID ANDREW GRIFFITH, DANIEL WEI-SHUNG KUNG
Abstract: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus.
Abstract: The present invention comprises cosmetic compositions and methods for retarding hair growth comprising a combination of an ornithine decarboxylase inhibitor, an anti-angiogenic active and an anti-inflammatory.
Type:
Application
Filed:
May 25, 2010
Publication date:
May 5, 2011
Inventors:
Mindy S. Goldstein, Chia Wen Chen, Christina G. Fthenakis, Kenneth D. Marenus, Thomas Mammone
Abstract: The present invention provides a method for the detection of early renal disease in animals. The method includes the steps of (a) obtaining a sample from an animal to be tested and (b) determining the amount of albumin in the sample. An amount of albumin in the range of from 10 ?g/ml to about 300 ?g/ml indicates the presence of early renal disease. The present invention also provides antibodies to canine, feline and equine albumin which can be used to detect the presence of early renal disease.
Type:
Grant
Filed:
January 26, 2007
Date of Patent:
May 3, 2011
Assignee:
Heska Corporation
Inventors:
Thomas McDonald, Wayne Arthur Jensen, Annika Weber, Janet S. Andrews
Abstract: Compositions for application to the skin of individuals in need thereof are provided that include media conditioned by the growth of human stem cells, particularly human neural stem cells. In some embodiments, the stem cells are grown without the use of feeder layers.
Abstract: An Echinozoa tissue or organ extract comprising antioxidant compounds is disclosed. Also disclosed is a process for obtaining an Echinozoa tissue or organ extract, as well an extract obtained by this process. Compositions comprising such an extract are also described. Uses of such extracts/compositions, as well as corresponding methods of treatment, for example as an antioxidant or to decrease or inhibit oxidative stress in a cell, tissue or subject are also described.
Abstract: A novel cellular component, tissue organizing structure, and methods for use in detection, diagnosis and treatment of disease is described herein. Particularly, clinical applications include tissue generation from individual cellular components, gene transfer therapeutics and its use as a novel target for cancer prevention and therapeutics. More particularly, methods for disease and cancer prevention, detection, diagnosis and treatment are provided.
Type:
Application
Filed:
August 6, 2008
Publication date:
April 21, 2011
Inventors:
Sarah C. Crawford, Herbert G. Potter, Tasino D. Herbert
Abstract: Disclosed are a method and a corresponding pharmaceutical composition for treating damaged cartilage and subchondral bone. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of cartilage and bone damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).
Abstract: Provided is a simple and easy method of producing an innoxious dry earthworm powder, while suppressing inactivation of the enzymes contained in earthworms. In the method, a homogenate obtained by grinding living earthworms is freeze-dried and the dried product is heat-treated at a temperature of 110° C. or higher but lower than 130° C. Preferably, the method according to the present invention comprises further a process for preparation of the living earthworms, which precedes the grinding step, comprising the steps of: standing the living earthworms under light for 10 to 50 hours; removing the dirt formed on the skin thereof, bringing the earthworms into contact with an organic acid for 30 seconds or less; diluting the acid with addition of water to adjust the pH of the aqueous acidic solution to a pH in the range of 2 to 5; standing the earthworm mixture under the pH condition for 3 to 180 minutes; and then washing the earthworms with water.
Abstract: Described herein are methods for identifying novel nucleic acid regulatory elements and compounds that modulate the regulation of such elements. Also described herein are nucleic acid sequence identified as novel nucleic acid regulatory elements and host cells containing such nucleic acid regulatory elements in a vector.
Type:
Application
Filed:
May 17, 2010
Publication date:
April 14, 2011
Inventors:
Anthony Giordano, Paul S. Eder, Deborah Beach McGill, Gregg Johannes
Abstract: Methods and devices for the stabilization of heart tissue to treat congestive heart failure using a therapeutic composition are discussed. The therapeutic composition can comprise an elastin stabilization agent, a collagen stabilization agent, or a combination thereof and be applied to the pericardium, to the outer surface of the myocardium, or a combination thereof using a catheter type of device with an attached reservoir. Controlled placement and release of the therapeutic composition can be achieved using a delivery vehicle to formulate the composition.